Zhongnuo Caring

Zhongnuo Caring is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of transformative gene therapies for rare and inherited diseases. The company's primary focus is on ophthalmology, utilizing its proprietary adeno-associated virus (AAV) platform to deliver functional genes to target tissues. Its lead program, ZN-001, is an AAV-based gene therapy designed to treat Leber Congenital Amaurosis (LCA) caused by RPE65 mutations, and it is currently undergoing clinical evaluation. Zhongnuo Caring integrates research, development, and internal GMP manufacturing capabilities to accelerate the translation of genetic science into clinical solutions. The company is backed by prominent venture capital firms and aims to address significant unmet medical needs in the field of genetic medicine.